Centre for Health and Bioinformatics


Professor Olaf Heidenreich

Professor of Molecular Haematology


My roles and responsibilities

Childhood Cancer Theme Leader

Institute GM Chair

Research Fellow of the University Sains Malaysia, Penang

My research interests

Leukaemic fusion genes as initiating and driving events in leukaemogenesis

Therapeutic interference with fusion gene function

Regulation of leukaemic self-renewal

Development of non-genotoxic treatments for childhood leukaemias

Current research group (shared with Josef Vormoor)

Helen Blair, PhD                                                        

Milene Dalmina, PhD student                                   

Alex Elder, PhD                                                        

Asmida Isa, PhD student

Hasan Issa, PhD student

Lynsey McKenzie, PhD

Hesta McNeill

Shalini Moorthy, PhD student

Ryan Nelson

Deepali Pal, PhD, NC3R Training Fellow

Ricky Tirtakusuma, PhD student


Research Interests

Oncogenic fusion genes

Current Work

Role of AML1/MTG8 (RUNX1/RUNX1T1) in leukaemic persistence
Role of MLL/AF4 (MLL/MLLT2) in leukaemic persistence
Systemic delivery of antileukaemic siRNAs

Esteem Indicators

Reviewer for the Leukaemia Research Fund, Children with Leukaemia, Cancer Research UK, Yorkshire Cancer Research.
Reviewer for Blood, Journal of Drug Targeting, Angewandte Chemie, Journal of Molecular and Cellular Medicine, Oligonucleotides, Cancer Letters, Expert Opinion on Therapeutic Targets, Oncogene, Cancer Investigation.


Primitive Progenitor/Stem Cells in Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia; Leukaemia Research Fund; £140,299, 01 Dec 2008 - 30 Nov 2010

The Role of RUNX1/RUNX1T1 in Therapy Induced Leukaemia (PhD studentship); JGW Patterson Foundation; £88,381; 01 Oct 2008 - 30 Sep 2011

The role of MLL/AF4 in Leukaemic Maintenance; Leukaemia Research Fund; £212,884; 01 Sep 2008 - 31 Aug 2011

AML1/MTG8 - an addictive oncogone? Kay Kendall Leukaemia Fund; £112,028; 01 Jul 2008 - 30 Jun 2010

NECCR PhD Studentship; North of England Childrens Cancer Research Fund; £32,242.33; 01 Mar 2007 - 30 Sep 2010


Eckstein F, Pieken W, Benseler F, Olsen DB, Williams DM, Heidenreich O: Modified ribozymes. 91916858; 23.09.1991

Heidenreich O, Vornlocher H-P, Kreutzer R, Limmer S: Method for inhibiting the expression of a target gene resulting from a chromosome aberration. EP 200300608; 22.01.2003

Heidenreich O, Hadwiger P, Vornlocher H-P: RNAi modulation of MLL-AF4 and uses thereof. US Serial No. 60/635,936; 6.12.2005